Cyclerion Therapeutics (CYCN)
(Delayed Data from NSDQ)
$3.50 USD
+0.28 (8.76%)
Updated Apr 19, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Cyclerion Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 2 | 4 | 2 | 5 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 2 | 4 | 2 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 46 | 59 | 84 | 130 |
Income After Depreciation & Amortization | -13 | -44 | -55 | -81 | -125 |
Non-Operating Income | 0 | 0 | 4 | 3 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -13 | -44 | -52 | -78 | -123 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -44 | -52 | -78 | -123 |
Extras & Discontinued Operations | 7 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -5 | -44 | -52 | -78 | -123 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -44 | -55 | -79 | -122 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 2 | 3 |
Income After Depreciation & Amortization | -13 | -44 | -55 | -81 | -125 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.34 | 2.17 | 1.96 | 1.52 | 1.37 |
Diluted EPS Before Non-Recurring Items | -3.98 | -20.20 | -26.40 | -51.20 | -89.80 |
Diluted Net EPS (GAAP) | -2.25 | -20.20 | -26.40 | -51.20 | -89.80 |
Fiscal Year end for Cyclerion Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.35 | 6.02 | 4.25 | 7.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.35 | -6.02 | -4.25 | -7.04 |
Non-Operating Income | NA | 0.10 | 0.11 | 0.06 | 0.09 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 4.45 | -5.91 | -4.18 | -6.95 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 4.45 | -5.91 | -4.18 | -6.95 |
Extras & Discontinued Operations | NA | -6.14 | 13.47 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.69 | 7.57 | -4.18 | -6.95 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 2.79 | 2.28 | 2.18 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.93 | -1.83 | -3.20 |
Diluted Net EPS (GAAP) | NA | 0.06 | 2.72 | -1.83 | -3.20 |